ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Hydrochloric Acid → methyl (S)-4-((R)-1-((S)-2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate

HRID 451889
印刷

反応式

HRID 451889 の反応式
Cl.[Cl:2][C:3]1[C:4]([F:25])=[C:5]([C@@:9]([OH:24])([C@@H:18]2[CH2:23][CH2:22][CH2:21][NH:20][CH2:19]2)[CH2:10][CH2:11][CH2:12][NH:13][C:14](=[O:17])[O:15][CH3:16])[CH:6]=[CH:7][CH:8]=1.[C:26]([O:30][C:31]([NH:33][C@@H:34]([CH2:49][CH:50]1[CH2:55][CH2:54][CH2:53][CH2:52][CH2:51]1)[CH2:35][NH:36][C:37](=O)[O:38]C1C=CC([N+]([O-])=O)=CC=1)=[O:32])([CH3:29])([CH3:28])[CH3:27].CCN(C(C)C)C(C)C>CC#N.C(Cl)Cl.CCOCC>[C:26]([O:30][C:31]([NH:33][C@@H:34]([CH2:49][CH:50]1[CH2:51][CH2:52][CH2:53][CH2:54][CH2:55]1)[CH2:35][NH:36][C:37]([N:20]1[CH2:21][CH2:22][CH2:23][C@@H:18]([C@@:9]([C:5]2[CH:6]=[CH:7][CH:8]=[C:3]([Cl:2])[C:4]=2[F:25])([OH:24])[CH2:10][CH2:11][CH2:12][NH:13][C:14](=[O:17])[O:15][CH3:16])[CH2:19]1)=[O:38])=[O:32])([CH3:29])([CH3:27])[CH3:28]
参加物実験手順後処理出典と根拠反応ノート

参加物

8

反応物 4

HCID 313Hydrochloric AcidHCID 81531DiisopropylethylamineHCID 59201293methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamateHCID 59382967(S)-4-nitrophenyl 2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamate

生成物 1

HCID 59201640
methyl (S)-4-((R)-1-((S)-2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
収率 68.2%

試薬・触媒・溶媒 3

HCID 3283Diethyl Ether溶媒HCID 6342Acetonitrile溶媒HCID 6344Dichloromethane溶媒

実験手順

To a stirred suspension of the HCl salt of methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate (31.6 mg, 0.08 mmol) and (S)-4-nitrophenyl 2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamate (45 mg, 0.105 mmol) in MeCN (1 mL) and CH2Cl2 (1 mL) was added DIEA (80 μL, 0.45 mmol). The mixture was stirred at rt for 3 d, diluted with ether (90 mL), washed with 5% aq HCl (20 mL), IM aq NaOH (20 mL) and brine (20 mL), and dried over MgSO4. Removal of the solvent left a white solid (61 mg) which was applied to a 2-g silica SPE cartridge. The cartridge was eluted sequentially with 0, 25, 50, 75 and 100% EtOAc in hexanes (15 mL of each) to afford five fractions. Fractions 4 and 5 were pooled and concentrated to afford methyl (S)-4-((R)-1-((S)-2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate (35 mg) as an oil.

後処理

  1. washwashed with 5% aq HCl (20 mL), IM aq NaOH (20 mL) and brine (20 mL)
  2. dry with materialdried over MgSO4
  3. customRemoval of the solvent
  4. waitleft a white solid (61 mg) which
  5. washThe cartridge was eluted sequentially with 0, 25, 50, 75 and 100% EtOAc in hexanes (15 mL of each)
  6. customto afford five fractions
  7. concentrationconcentrated

出典と根拠

ORDレコード
ord-7af8b3f4936e4b6388428b4a1c6887b6
出典データセット
uspto-grants-2013_07
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08487108B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート